Q32 Bio Inc.: RA CAPITAL MANAGEMENT, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
RA Capital Management amended its Schedule 13G filing on Q32 Bio Inc., updating its beneficial ownership stake in the clinical-stage biotech, per SEC accession 0001346824-26-000293. The filing's specific share count and percentage were not detailed in the headline disclosure. Schedule 13G amendments are typically watched for signals of passive institutional positioning in small-cap biotech names. Investors will look to the full filing for exact ownership figures and any change from prior reported levels.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Q32 Bio Inc., RA Capital Management, L.P.